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INTRODUCTION
Chronic hepatitis B (CHB) is known to be the most common 
chronic viral infection, affecting approximately 350 million people 
worldwide.1 Since the persistent replication with necroinflamma-
tion by the hepatitis B virus (HBV) significantly raises the risk of 
developing compensated cirrhosis and hepatocellular carcinoma 
(HCC),2 antiviral therapy to suppress HBV replication, which can 
prevent the progression of liver disease by stabilizing necroinflam-
mation and inducing fibrosis regression, has been the mainstay in 
the management of patients with CHB.3 Several recent studies 
have proven that oral antiviral agents, particularly entecavir (ETV), 
reduce the risk of long-term complications such as liver cirrhosis 
and HCC, ultimately improving survival compared to controls.4
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Although tenofovir alafenamide and besifovir dipivoxil maleate 
have been recently available,3,5 ETV and tenofovir disoproxil fuma-
rate (TDF), which are potent nucleos(t)ide analogues (NUCs) with 
a high genetic barrier to resistance, have been the first-line antivi-
ral agents in several international guidelines over the last several 
decades.3,6,7 These two antiviral agents have similar short to inter-
mediate-term clinical efficacy (including virologic, biochemical, 
serologic, and histologic responses) and similar efficacy for pre-
venting liver disease progression.8,9 However, several recent stud-
ies have proposed the superiority of TDF over ETV in reducing the 
risk of HCC development,10 whereas other following studies have 
shown no statistical difference.11,12
In this review, we summarized recent studies which compared 
the treatment efficacy of ETV and TDF in terms of HCC development.




Since Choi et al.10 first reported that TDF showed superior ef-
fects compared to ETV for the prevention of HCC, more than 10 
comparative studies between ETV and TDF with adjusted hazard 
ratio (aHR) for HCC incidence have been published, as summa-
rized in Tables 1, 2 and Figure 1.
A multicenter retrospective cohort study from Korea analyzed 
2,897 patients, and the annual HCC incidence was statistically 
similar between the ETV and TDF groups in multivariate analysis 
(aHR, 0.98; 95% confidence intervals [CIs], 0.75–1.28; P=0.852), 
propensity score-matched (PSM) analysis (aHR, 1.02; 95% CIs, 
0.77–1.35; P =0.884), and inverse probability of treatment 
weighting (IPTW) analysis (aHR, 1.00; 95% CIs, 0.77–1.30; 
P=0.988) (Table 1).11
Another multicenter retrospective cohort study from Korea ana-
lyzed 3,022 patients, and found statistically similar incidence rates 
of HCC between ETV and TDF after PSM in the whole cohort (aHR, 
1.08; 95% CIs, 0.52–2.24; P=0.842) and in subgroups of patients 
with chronic hepatitis and liver cirrhosis. In addition, statistically 
similar incidence rates of all-cause mortality or liver transplanta-
tion (LT) between ETV and TDF were observed after PSM in the 
whole cohort (aHR, 0.98; 95% CIs, 0.36–2.62; P=0.961) and in 
patients with chronic hepatitis and liver cirrhosis (Fig. 1).12
A multicenter retrospective cohort study from Taiwan analyzed 
7,248 patients. The HCC incidence rates of ETV and TDF groups 
were statistical similar in the whole cohort (aHR, 0.82; 95% CIs, 
0.66–1.02; P=0.078) and in the PSM cohort (aHR, 0.83; 95% CIs, 
0.65–1.06; P=0.129).13
A single-center retrospective cohort study from Korea analyzed 
1,340 patients, and showed that HCC risk was statistically similar 
between ETV and TDF groups, either by PSM (aHR, 2.06; 95% 
CIs, 0.98–4.33; P=0.058) or IPTW (aHR, 1.30; 95% CIs, 0.81–
2.10; P=0.276).14
A single-center retrospective cohort study from Korea analyzed 
1,794 patients. Multivariate analysis showed that the risk of HCC 
and death or LT was statistically similar between ETV and TDF 
groups (aHR, 0.83; 95% CIs, 0.52–1.31; P=0.413 and aHR, 0.64; 
95% CIs, 0.26–1.57; P=0.325, respectively) after adjusting for 
adherence to medication and maintained virologic response. In 
the 589 PSM patients, the risk of HCC and death or LT was also 
statistically similar between the two groups (aHR, 0.77; 95% CIs, 
0.46–1.29; P=0.319 and aHR, 0.64; 95% CIs, 0.30–1.38; P=0.257, 
respectively).15
In a retrospective cohort study by an Asian international con-
sortium which analyzed 5,537 patients, TDF was associated with 
a lower risk of HCC in the unadjusted analysis. However, in the 
multivariate analysis, no difference was found between ETV and 
TDF (aHR, 0.81; 95% CIs, 0.42–1.56; P=0.52) after adjustment 
for age, sex, country, serum albumin, platelet count, alpha feto-
protein, liver cirrhosis, and diabetes mellitus. Furthermore, PSM 
analysis (n=1,040) found no significant association between anti-
viral agents and HCC risk in the multivariable-adjusted analysis 
(aHR, 0.89; 95% CIs, 0.41–1.92; P=0.77).16
In a multicenter retrospective study from Korea which analyzed 
1,560 patients, the incidence of HCC was statistically similar be-
tween ETV and TDF groups after multivariate analysis and in the 
PSM population (aHR, 1.30; 95% CIs, 0.80–2.02; P=0.295).17
Even before Choi et al.10 suggested the superiority of TDF for 
the prevention of HCC, a single-center retrospective study from 
Korea had analyzed 582 patients for a median follow-up of 57 
months and compared the effects of ETV and TDF. In this study, 
HCC developed in 6.5% of the patients, regardless of the type of 
antiviral agents. ETV and TDF-treated patients showed statistical-
ly similar HCC development rates (P=0.471).18
From a slightly different perspective, one Korean multicenter 
retrospective cohort study compared the effects of ETV and TDF 
in 726 patients following curative treatments of HCC, such as he-
patic resection or radiofrequency ablation. The results showed no 
association between the type of antiviral agents and HCC recur-
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rence (aHR, 0.93; 95% CIs, 0.70–1.23; P=0.622) and death (aHR, 
0.67; 95% CIs, 0.36–1.23; P=0.193) after multivariate analysis. 
IPTW analysis showed similar results in terms of recurrence (aHR, 
1.04; P=0.963) and death (aHR, 0.80; P=0.431). In addition, the 
early (<2 years) and late (≥2 years) recurrence risks were statisti-
cally similar in the two groups (both P=0.400), as confirmed by 
IPTW analysis (P=0.502 and P=0.377, respectively).19
Western studies
A multicenter prospective study from Europe that enrolled pa-
tients from the PAGE-B cohort analyzed 1,935 Caucasians with 
CHB, with or without compensated liver cirrhosis, for a median 
follow-up period of 7.1 years. After multivariate analysis, the haz-
ard ratio of HCC was statistically similar between ETV and TDF-
treated patients after adjusting for several HCC risk factors, such 
as age, sex, smoking, diabetes, alanine aminotransferase (ALT) 
level, platelet count, hepatitis B e antigen, prior treatment experi-
ence, and liver cirrhosis (aHR, 1.07; 95% CIs, 0.64–1.81; P=0.791).20
Another multicenter prospective cohort study from France in-
cluded 1,800 patients for a median follow-up period of 4.2 years. 
The HCC incidence (aHR, 1.51; 95% CIs, 0.58–3.92) and all-cause 
mortality (aHR, 0.60; 95% CIs, 0.25–1.46) were statistically simi-
lar between the ETV and TDF-treated groups. In addition, IPTW 
analysis showed similar results in HCC occurrence (aHR, 1.24; 
95% CIs, 0.49–3.13) and all-cause mortality (aHR, 0.63; 95% CIs, 
0.28–1.44).21
Studies using administrative databases
Asian study
A large-scale retrospective cohort study using nationwide 
claims data from the Korean Health Insurance Review and Assess-
ment Service enrolled 76,285 patients.22 This study analyzed 
55,473 treatment-naïve cases where ETV or TDF treatment were 
started between 2013 and 2017 after matching according to age, 
sex, comorbidities, hospital type, and index date year for a medi-
an follow-up period of 41.2 months. The incidence of HCC was 
statistically similar between the ETV and TDF groups (aHR, 0.93; 
95% CIs, 0.86–1.01; P=0.081). Interestingly, in the subgroup 
analysis of patients who had started antiviral therapy during the 
2012–2014 period, which was identical to the enrollment period 
in the landmark study by Choi et al.,10 the incidence of HCC was 
higher in the ETV group compared to the TDF group (aHRs, 0.85; 
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Western study
A retrospective cohort study using the Corporate Data Ware-
house from the Veterans Information Systems and Technology Ar-
chitecture in the United States analyzed 3,287 patients with a 
mean follow-up period of 5.4 years. In the unadjusted analysis, a 
lower tendency of HCC occurrence was observed in the ETV group 
compared to the TDF group. However, PSM analysis showed simi-
lar risk of HCC between ETV and TDF-treated patients (aHR, 1.00; 
95% CIs, 0.76–1.32). Also, statistically similar risk of death or LT 
(aHR, 1.16; 95% CIs, 0.98–1.39) was observed between the two 
treatment groups.23
TENOFOVIR IS BETTER THAN ENTECAVIR FOR 
THE PREVENTION OF HCC
Hospital-based cohort studies
Asian studies
A large-scale single-center study by Choi et al.10 was the first to 
report that TDF treatment had a significantly lower risk of HCC 
compared to ETV treatment (Table 2). This study demonstrated 
that patients treated with TDF, compared with ETV, showed 34% 
and 32% reductions in their risk for HCC by multivariable and 
PSM analyses, respectively.10 In addition, patients treated with 
TDF showed significantly higher virological responses (85.2% 
[TDF] vs. 78.7% [ETV], P<0.001) and ALT normalization rates, ac-
cording to the American Association for the Study of Liver Diseas-
es 2015 criteria (44.3% [TDF] vs. 38.7% [ETV], P=0.002) after 
1 year of treatment.10
Another single-center Korean study of 404 treatment-naïve pa-
tients with CHB showed that TDF treatment was associated with 
a lower HCC risk by multivariable analysis (aHR, 0.31; 95% CIs, 
0.12–0.79; P=0.014) and PSM analysis (aHR, 0.27; 95% CIs, 
0.08–0.98; P=0.046).24 Interestingly, when the authors adjusted 
for sustained virological suppression in their PSM analysis, statis-
tical significance was not reached, despite a persistent trend of 
lower risk with TDF treatment (aHR, 0.36; 95% CIs, 0.12–1.14; 
P=0.08). Theoretically, however, it is not possible to measure sus-
tained virological suppression at baseline. Therefore, adding this 
variable into PSM might not be statistically justifiable.
Choi et al.25 also studied 1,695 patients with HBV-related HCC 
of Barcelona Clinic Liver Cancer stage of 0 or A to see whether 
TDF treatment has a lower risk of HCC recurrence after curative-
Figure 1. Forest plot of the incidence rates of hepatocellular carcinoma in studies that compared preventive effects of TDF and ETV after the match-
ing of baseline variables. CI, confidence interval; TDF, tenofovir disoproxil fumarate; ETV, entecavir.
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intent liver resection compared to ETV treatment. Notably, TDF 
treatment was associated with significantly lower rates of HCC re-
currence (aHR, 0.82; 95% CIs, 0.68–0.98; P=0.03) and death or 
transplantation (aHR, 0.62; 95% CIs, 0.44–0.88; P=0.01) by mul-
tivariable analysis. These findings were consistently reproduced in 
567 PSM pairs (HR, 0.77; 95% CIs, 0.62–0.95; P=0.02 for HCC 
recurrence and HR, 0.63; 95% CIs, 0.42–0.96; P=0.03 for death 
or transplantation). Interestingly, the magnitude of risk difference 
for late recurrence (≥2 years after liver resection; HR, 0.68) was 
more prominent than that for early recurrence (<2 years after liver 
resection; HR, 0.79).25
A Chinese study of 233 patients with CHB-related compensated 
cirrhosis showed that TDF treatment led to significantly longer 
disease-free survival compared to ETV treatment after liver resec-
tion (33 months for TDF and 24 months for ETV, P<0.001).26 An-
other study from China also reported that TDF treatment was as-
sociated with a significantly lower rate of HCC recurrence (aHR, 
0.67; 95% CIs, 0.48–0.93; P=0.04) after liver resection compared 
to non-TDF treatment, such as ETV.27
A multicenter retrospective study from Taiwan, which included 
1,560 cirrhotic patients with CHB, reported that TDF treatment 
was significantly associated with a lower risk of HCC compared to 
ETV treatment, as shown by multivariable analysis (aHR, 0.67; 
95% CIs, 0.48–0.93; P=0.02), PSM analysis (aHR, 0.66; 95% CIs, 
0.46–0.95; P=0.02), and IPTW analysis (aHR, 0.73; 95% CIs, 
0.54–0.98; P=0.04).28 Of note, the significantly lower risk of HCC 
in the TDF group was consistently observed in the subgroup anal-
yses of treatment-naïve patients (aHR, 0.58; 95% CIs, 0.40–0.84; 
P=0.004) and patients with compensated cirrhosis at baseline 
(aHR, 0.69; 95% CIs, 0.48–1.00; P=0.049).28 However, compara-
ble risk of HCC was observed between the two treatment groups 
after excluding 398 patients (25.5%) who were enrolled after 
2011, to prevent artificially minimizing the follow-up duration be-
tween the two treatments (P=0.881 for PSM and P=0.879 for 
IPTW analysis).28
Studies using administrative databases
Asian studies
A nationwide cohort study from Korea was the first to report 
the lower risk of HCC with TDF treatment than with ETV treat-
ment.10 In this study, the risk of HCC was compared among 24,156 
treatment-naïve patients with CHB, and the results showed that 
TDF treatment was significantly associated with a lower risk of 
HCC compared to ETV treatment (aHR, 0.68; 95% CIs, 0.59–0.77; 
P<0.001).10 This lower risk of HCC in the TDF treatment group was 
reproduced in the PSM analysis of 10,923 pairs (aHR, 0.68; 95% 
CIs, 0.60–0.78; P<0.001).
Another study from Hong Kong, which used a large administra-
tive database, subsequently showed a lower risk of HCC in the 
TDF group compared to the ETV group.29 In 29,350 treatment-na-
ïve patients with CHB and a median follow-up period of 3.6 years, 
TDF treatment was consistently associated with a lower risk of 
HCC compared to ETV (weighted subdistribution; HR, 0.36; 95% 
CIs, 0.16–0.80; P=0.013). These results were supported by vari-
ous sophisticated statistical adjustments including multivariable, 
PSM, IPTW, and competitive risk analyses to minimize selection 
bias in the retrospective study. Additionally, in this study, patients 
who were treated with TDF (77.6%) showed a significantly higher 
virological response at 1 year compared to those who were treat-
ed with ETV (69.7%), although ALT normalization rate at 1 year 
was higher in the ETV group compared to the TDF group.
Western study
A study published as a collection of meeting abstracts analyzed 
the U.S. administrative data comparing TDF and ETV treatments 
in terms of the risk of HCC in treatment-naïve patients with CHB.30 
In this study, the absolute rate of HCC was lower in those treated 
with TDF (0.32 person year [PY]) than in those treated with ETV 
(0.61 PY). In addition, multivariable analysis and weighting by 
propensity score showed that treatment with TDF was associated 
with a significantly decreased risk of HCC occurrence (aHR, 0.56; 
95% CIs, 0.37–0.86).30
DISCUSSION
In the current study, we have comprehensively reviewed recent 
comparative studies regarding the effects of ETV and TDF on the 
prevention of HCC. We have classified the studies according to re-
gions in which the studies were conducted as well as the data 
sources, in order to observe the potential difference in the results 
depending on regions or whether the data was collected from 
hospital cohorts or administrative databases.
The studies that showed no difference in preventive effects be-
tween ETV and TDF have suggested the following evidence for 
their equal effects. First, the common features of the studies that 
suggested TDF superiority mostly used big data from administra-
tive databases. These database studies have an advantage of in-
cluding a large number of patients. However, they may also have 
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some disadvantages, such as potential unbalanced distribution of 
HCC risk factors, different periods of ETV and TDF onset, and ad-
ditional confounders that cannot be corrected for by any sophisti-
cated statistical method.31 For example, in the study by Yip et 
al.,29 one-third of the HBV DNA values and 21% of the prothrom-
bin time values, which may be important factors for the analysis 
of HCC development in CHB patients, were missing, and there-
fore, had to be imputed before the analysis was performed. In ad-
dition, out of the 29,350 patients analyzed, there was a big dif-
ference in the number of patients included in each group; 28,041 
patients were included in the ETV group, while only 1,309 pa-
tients were in the TDF group. Correspondingly, only eight cases of 
HCC were observed in the TDF group, which may have been too 
small a number of events to effectively compare the HCC inci-
dence between the two groups. In addition, the HR was 0.39 in 
this study, which indicates that TDF lowers HCC incidence by 61% 
compared to ETV. However, in the study by Nguyen et al.32 that 
compared the incidence of HCC between TDF and no treatment, 
the HR was similar at 0.34. As ETV has demonstrated its protec-
tive effect against HCC in numerous studies, it is highly unlikely 
for ETV treatment to have similar effects as no treatment.
Second, there was no clear evidence that ETV contains carcino-
genic property. Although an increase in lung and vascular tumors 
were observed in the mouse experiment, the doses used in such 
experiments were more than 100-fold higher compared to the ap-
proved dose for humans. Furthermore, a long-term study that in-
cluded more than 12,000 patients showed no difference in HCC 
and non-HCC malignancies between ETV and other NUCs.33
Third, the patient warehousing phenomenon may have resulted 
in TDF superiority in some studies. The patient warehousing phe-
nomenon indicates that deferring treatment as a new effective 
drug is known to be released soon. As ETV was approved a few 
years earlier than TDF in most countries, more patients with se-
vere chronic liver disease, who had been waiting for more potent 
newly available antiviral agent, may have been included in the 
ETV group. In addition, TDF may have been avoided in the elderly 
as well as patients with co-morbidities, due to concerns of renal 
toxicity and osteoporosis.16 In this context, the pooled 5-year cu-
mulative HCC incidence in the most recently published meta-anal-
ysis involving more than 100,000 patients showed that TDF had 
significantly superior preventive effects in the unmatched popula-
tion while no difference was observed in the PSM population, 
which may indicate the patient warehousing phenomenon.34 Simi-
larly, expansion in the indication for treatment in guidelines and 
the consequent changes in the reimbursement criteria for antiviral 
therapy over the years may have resulted in the inclusion of less 
severe patients in the TDF group. For instance, in Korea, the reim-
bursement criteria for cirrhotic patients used to require ALT higher 
than the upper limits of normal prior to 2015, but these have ex-
panded to include patients with normal ALT levels since 2015. As 
ETV had been approved in 2007 and TDF in 2012, more patients 
in the TDF group may have initiated antiviral therapy after like-
wise expansion in reimbursement criteria and indications for 
treatment.
In contrast, the studies showing superior preventive effects of 
TDF compared to ETV have suggested the following evidence for 
their differences. First, TDF might have more potent antiviral effi-
cacy. In the study by Choi et al.,10 TDF treatment showed signifi-
cantly higher rates of virological response and ALT normalization 
at 1 year of antiviral treatment in the entire cohort and PSM. A 
small randomized trial comparing ETV and TDF of antiviral effica-
cy demonstrated a higher hepatitis B surface antigen level reduc-
tion in patients treated with TDF compared to those treated with 
ETV.35 These results might be linked to the superior preventive ef-
fects of TDF in reducing the HCC risk, albeit the difference in anti-
viral efficacy may be small.
Second, a meta-regression analysis showed that the inclusion of 
decompensated cirrhosis was one of the most important determi-
nants showing superiority of the preventive effect of TDF in reduc-
ing the risk of HCC.36 In other words, studies that included de-
compensated cirrhosis tended to show favorable outcomes by TDF 
in the risk of HCC compared to ETV. Previous studies already 
demonstrated that long-term antiviral treatment can lead to im-
provement and regression of cirrhosis in patients with CHB.37 
Therefore, TDF may have better preventive effect in this subset of 
patients.
Third, a possible biological plausibility of superior preventive ef-
fects of TDF compared to ETV was suggested in previous studies, 
in which a higher interferon lambda-3 level was shown in CHB 
patients treated with TDF than in those treated with ETV.38 Also, 
a potent antitumor activity of the interferon lambda-3 pathway 
was shown in animal models of cancer, including HCC.39,40
Lastly, most of the meta-analyses,36,41-44 but not all,34 in this 
comparison exhibited superior chemo-preventive effect by TDF 
treatment compared to ETV treatment. Since meta-analysis col-
lects numerous studies of the same topic, it is able to show a real 
difference that was not either statistically significant or captured 
due to small sample size in individual studies, if the real difference 
still exists.
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CONCLUSIONS
Although a larger number of studies have favored a similar effi-
cacy between ETV and TDF in reducing the risk of HCC develop-
ment, controversy remains on whether TDF reduces the risk of 
HCC to a greater extent compared to ETV. Several recent studies 
from Asia, Europe, and the U.S. did not reproduce the original 
findings of the study by Choi et al.,10 which might suggest that the 
current practice and guidelines for using ETV and TDF in patients 
with CHB should not be changed. However, as all of these studies 
were either neutral or in favor of TDF, further studies are required 
to identify the subset of patient population who will benefit from 
TDF, rather than ETV.
Authors’ contributions
SWL, JC, SUK, and YSL were involved in study concept and de-
sign; SWL, JC, SUK, and YSL were involved in critical revision of 
the manuscript; SWL, JC, and SUK were involved in acquisition of 
data and drafting of the manuscript. All authors have read and 
approved the manuscript.
Conflicts of Interest
The authors have no conflicts to disclose.
REFERENCES
  1. Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural his-
tory, pathogenesis and treatment of chronic hepatitis B. Antivir Ther 
2011;16:1169-1186.
  2. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepato-
cellular carcinoma across a biological gradient of serum hepatitis B 
virus DNA level. JAMA 2006;295:65-73.
  3. Korean Association for the Study of the Liver (KASL). KASL clinical 
practice guidelines for management of chronic hepatitis B. Clin Mol 
Hepatol 2019;25:93-159.
  4. Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, et al. Enteca-
vir treatment reduces hepatic events and deaths in chronic hepatitis 
B patients with liver cirrhosis. Hepatology 2013;58:1537-1547.
  5. Song DS, Kim W, Ahn SH, Yim HJ, Jang JY, Kweon YO, et al. Con-
tinuing besifovir dipivoxil maleate versus switching from tenofovir 
disoproxil fumarate for treatment of chronic hepatitis B: results of 
192-week phase 3 trial. Clin Mol Hepatol 2021;27:346-359.
  6. European Association for the Study of the Liver. EASL 2017 clinical 
practice guidelines on the management of hepatitis B virus infec-
tion. J Hepatol 2017;67:370-398.
  7. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas 
MM, et al. Update on prevention, diagnosis, and treatment of 
chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 
2018;67:1560-1599.
  8. Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Bo-
emmel F, et al. The risk of hepatocellular carcinoma decreases after 
the first 5 years of entecavir or tenofovir in Caucasians with chronic 
hepatitis B. Hepatology 2017;66:1444-1453.
  9. Kim BG, Park NH, Lee SB, Lee H, Lee BU, Park JH, et al. Mortality, 
liver transplantation and hepatic complications in patients with 
treatment-naïve chronic hepatitis B treated with entecavir vs tenofo-
vir. J Viral Hepat 2018;25:1565-1575.
10. Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of hepatocel-
lular carcinoma in patients treated with entecavir vs tenofovir for 
chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol 
2019;5:30-36.
11. Kim SU, Seo YS, Lee HA, Kim MN, Lee YR, Lee HW, et al. A multi-
center study of entecavir vs. tenofovir on prognosis of treatment-
naïve chronic hepatitis B in South Korea. J Hepatol 2019;71:456-464.
12. Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS, et al. Com-
parison of tenofovir and entecavir on the risk of hepatocellular 
carcinoma and mortality in treatment-naïve patients with chronic 
hepatitis B in Korea: a large-scale, propensity score analysis. Gut 
2020;69:1301-1308.
13. Chang TS, Yang YH, Chen WM, Shen CH, Tung SY, Yen CW, et al. 
Long-term risk of primary liver cancers in entecavir versus tenofovir 
treatment for chronic hepatitis B. Sci Rep 2021;11:1365.
14. Ha I, Chung JW, Jang ES, Jeong SH, Kim JW. Comparison of the on-
treatment risks for hepatocellular carcinoma between entecavir and 
tenofovir: a propensity score matching analysis. J Gastroenterol 
Hepatol 2020;35:1774-1781.
15. Shin JW, Jeong J, Jung SW, Lee SB, Park BR, Kim MJ, et al. Compara-
ble incidence of hepatocellular carcinoma in chronic hepatitis B pa-
tients treated with entecavir or tenofovir. Dig Dis Sci 2021;66:1739-
1750.
16. Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, et al. 
Tenofovir versus entecavir for hepatocellular carcinoma prevention 
in an international consortium of chronic hepatitis B. Am J Gastro-
enterol 2020;115:271-280.
17. Oh H, Yoon EL, Jun DW, Ahn SB, Lee HY, Jeong JY, et al. No dif-
ference in incidence of hepatocellular carcinoma in patients with 
chronic hepatitis b virus infection treated with entecavir vs tenofovir. 
Clin Gastroenterol Hepatol 2020;18:2793-2802.e6.
18. Yu JH, Jin YJ, Lee JW, Lee DH. Remaining hepatocellular carcinoma 
risk in chronic hepatitis B patients receiving entecavir/tenofovir in 
South Korea. Hepatol Res 2018;48:862-871.
19. Lee JH, Kim BK, Park SY, Tak WY, Park JY, Kim DY, et al. The ef-
ficacies of entecavir and tenofovir in terms of enhancing prognosis 
412 http://www.e-cmh.orghttps://doi.org/10.3350/cmh.2021.0179
Volume_27  Number_3  July 2021
after curative treatment of hepatitis B virus-related hepatocel-
lular carcinoma. Eur J Intern Med. 2021 Mar 30. doi: 10.1016/
j.ejim.2021.02.019.
20. Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boem-
mel F, Buti M, et al. Similar risk of hepatocellular carcinoma during 
long-term entecavir or tenofovir therapy in Caucasian patients with 
chronic hepatitis B. J Hepatol 2020;73:1037-1045.
21. Pol S; ANRS/AFEF study group. Similar 5-year HCC occurrence 
in tenofovir- and entecavir-treated HBV chronic infection in the 
French AFEF/ANRS CO22 hepather cohort. Aliment Pharmacol Ther 
2021;53:616-629.
22. Choi H, Seo GH. Entecavir versus tenofovir for the prevention of 
hepatocellular carcinoma in treatment-naïve chronic hepatitis B pa-
tients in Korea. J Korean Med Sci 2021;36:e89.
23. Su F, Berry K, Ioannou GN. No difference in hepatocellular carcino-
ma risk between chronic hepatitis B patients treated with entecavir 
versus tenofovir. Gut 2021;70:370-378.
24. Ha Y, Chon YE, Kim MN, Lee JH, Hwang SG. Hepatocellular carcino-
ma and death and transplantation in chronic hepatitis B treated with 
entecavir or tenofovir disoproxil fumarate. Sci Rep 2020;10:13537.
25. Choi J, Jo C, Lim YS. Tenofovir versus Entecavir on recurrence of 
hepatitis B virus-related hepatocellular carcinoma after surgical re-
section. Hepatology 2021;73:661-673.
26. Zhang M, Wang D, Liu H, Li H. Tenofovir decrease hepatocellular 
carcinoma recurrence in chronic hepatitis B patients after liver re-
section. Infect Agent Cancer 2018;13:19.
27. Ge Z, Ma J, Qiao B, Wang Y, Zhang H, Gou W. Impact of tenofovir 
antiviral treatment on survival of chronic hepatitis B related hepa-
tocellular carcinoma after hepatectomy in Chinese individuals from 
Qingdao municipality. Medicine (Baltimore) 2020;99:e21454.
28. Chen CH, Chen CY, Wang JH, Lai HC, Hung CH, Lu SN, et al. Com-
parison of incidence of hepatocellular carcinoma between chronic 
hepatitis B patients with cirrhosis treated with entecavir or tenofovir 
in Taiwan - a retrospective study. Am J Cancer Res 2020;10:3882-
3895.
29. Yip TC, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL. Tenofovir is 
associated with lower risk of hepatocellular carcinoma than enteca-
vir in patients with chronic HBV infection in China. Gastroenterology 
2020;158:215-225.e6.
30. Kim WR, Telep L, Lu M, Ramroth H, Flaherty JF, Gaggar A, et al. Risk 
of incident hepatocellular carcinoma in hepatitis B-infected patients 
treated with tenofovir disoproxil fumarate versus entecavir: a US 
administrative claims analysis. Hepatology 2019;70:302A-303A.
31. Lampertico P, Papatheodoridis GV. Is tenofovir superior to entecavir 
in reducing the risk of hepatocellular carcinoma in chronic hepatitis 
B? The controversy continues. Gastroenterology 2020;158:42-44.
32. Nguyen MH, Yang HI, Le A, Henry L, Nguyen N, Lee MH, et al. 
Reduced incidence of hepatocellular carcinoma in cirrhotic and non-
cirrhotic patients with chronic hepatitis B treated with tenofovir-A 
propensity score-matched study. J Infect Dis 2019;219:10-18.
33. Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, et al. 
Outcomes of long-term treatment of chronic HBV infection with en-
tecavir or other agents from a randomized trial in 24 countries. Clin 
Gastroenterol Hepatol 2020;18:457-467.e21.
34. Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, et al. Hepatocel-
lular carcinoma incidence with tenofovir versus entecavir in chronic 
hepatitis B: a systematic review and meta-analysis. Lancet Gastro-
enterol Hepatol 2020;5:1039-1052.
35. Koike K, Suyama K, Ito H, Itoh H, Sugiura W. Randomized prospec-
tive study showing the non-inferiority of tenofovir to entecavir in 
treatment-naïve chronic hepatitis B patients. Hepatol Res 2018;48: 
59-68.
36. Choi WM, Choi J, Lim YS. Effects of tenofovir vs entecavir on risk 
of hepatocellular carcinoma in patients with chronic HBV infection: 
a systematic review and meta-analysis. Clin Gastroenterol Hepatol 
2021;19:246-258.e9.
37. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. 
Regression of cirrhosis during treatment with tenofovir disoproxil fu-
marate for chronic hepatitis B: a 5-year open-label follow-up study. 
Lancet 2013;381:468-475.
38. Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka 
E, et al. Induction of IFN-lambda3 as an additional effect of nucleo-
tide, not nucleoside, analogues: a new potential target for HBV 
infection. Gut 2018;67:362-371.
39. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. Antitu-
mor activity of IFN-lambda in murine tumor models. J Immunol 
2006;176:7686-7694.
40. Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche 
E, et al. Antitumor activity of type I and type III interferons in BNL 
hepatoma model. Cancer Immunol Immunother 2010;59:1059-1071.
41. Dave S, Park S, Murad MH, Barnard A, Prokop L, Adams LA, et al. 
Comparative effectiveness of entecavir versus tenofovir for prevent-
ing hepatocellular carcinoma in patients with chronic hepatitis B: a 
systematic review and meta-analysis. Hepatology 2021;73:68-78.
42. Li M, Lv T, Wu S, Wei W, Wu X, Ou X, et al. Tenofovir versus ente-
cavir in lowering the risk of hepatocellular carcinoma development 
in patients with chronic hepatitis B: a critical systematic review and 
meta-analysis. Hepatol Int 2020;14:105-114.
43. Gu L, Yao Q, Shen Z, He Y, Ng DM, Yang T, et al. Comparison of 
tenofovir versus entecavir on reducing incidence of hepatocellular 
carcinoma in chronic hepatitis B patients: a systematic review and 
meta-analysis. J Gastroenterol Hepatol 2020;35:1467-1476.
44. Liu H, Shi Y, Hayden JC, Ryan PM, Rahmani J, Yu G. Tenofovir treat-
ment has lower risk of hepatocellular carcinoma than entecavir 
treatment in patients with chronic hepatitis B: a systematic review 
and meta-analysis. Liver Cancer 2020;9:468-476.
